Vitale, Ilio
Shema, Efrat http://orcid.org/0000-0002-3718-593X
Loi, Sherene http://orcid.org/0000-0001-6137-9171
Galluzzi, Lorenzo http://orcid.org/0000-0003-2257-8500
Article History
Received: 26 July 2020
Accepted: 7 January 2021
First Online: 11 February 2021
Competing interests
: S.L. receives research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Roche-Genentech, Puma Biotechnology, Pfizer, Eli Lilly, and Seattle Genetics, and she has acted as a noncompensated consultant for Seattle Genetics, Pfizer, Novartis, BMS, Merck, AstraZeneca, and Roche-Genentech, as well as compensated consultant for Aduro Biotech, Novartis, GlaxoSmithKline, and G1 Therapeutics. L.G. has received research funding from Lytix and Phosplatin, as well as consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, The Longevity Labs, Inzen, and the Luke Heller TECPR2 Foundation.